Objective:
The article discusses centralized imaging services in ophthalmology clinical trials and previews AI-based endpoints for dry age-related macular degeneration (AMD) and geographic atrophy (GA).
Approach:
- Centralized imaging: Yijun Huang described Merit as an independent reading center that brings together data from multisite trials, reviews them in a blinded manner, interfaces with sites, and uses a technology platform with an audit trail for quality assurance.
- AI-based endpoints: David P. Bingaman previewed a presentation on AI-based endpoints using en face optical coherence tomography (OCT) images for dry AMD, including geographic atrophy (GA) and high-risk intermediate AMD.
Key Findings:
- Endpoints discussed included total GA lesion area and, for high-risk intermediate AMD, hyperreflective foci, drusen volume, and choroidal hypertransmission defects.
- Bingaman said Merit participated in just over 200 ophthalmology clinical trials globally in the prior year, including 45 conducted in China.
Interpretation:
The speakers described centralized, blinded image review and site data coordination, and previewed AI-based OCT measures as potential endpoints for dry AMD and GA.
Limitations:
- The source is an edited interview and does not report methods or quantitative validation or performance results for the AI-based endpoints.
Conclusion:
Huang described Merit’s role in coordinating and quality-checking imaging data for clinical trials. Bingaman previewed AI-based OCT endpoints for dry AMD, including GA and high-risk intermediate AMD.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
